Biopharma stocks jump as Americans vote for Trump
10 November 2016
An audible sigh of relief was heard this morning that, at last, the U.S. 2016 election is over. In the end, in what was an oft-controversial, hot-tempered and at times bewildering contest between two bitter rivals--and in what 18 months ago seemed impossible--Republican Donald Trump has become the president-elect of the United States.
Trust issues: Millennials are more skeptical of pharma than older generations
10 November 2016
Millennials on both sides of the healthcare coin are skeptical of pharma companies. Both younger patients and doctors don’t trust Big Pharma, according to doctor social network Sermo. And it may be the drug companies’ fault.
Research on new, rapid screening test identifies potential therapies against drug-resistant bacteria
10 November 2016
Researchers at the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), Clinical Center and National Institute of Allergy and Infectious Diseases (NIAID) have created a new way to identify drugs and drug combinations that may potentially be useful in combating infections that are resistant to many different antibiotics. They developed an assay (test) to rapidly screen thousands of drugs to determine how effective they were against a variety of types of resistant bacteria.
09 November 2016
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter ended September 30, 2016 and provided an update on its development programs.
Miramar Labs, Inc. ® Reports Record Third Quarter 2016 Financial Results
09 November 2016
Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today financial results for the third quarter ended September 30, 2016.
Stanford readies for CRISPR human testing after sickle cell success
09 November 2016
Scientists from Stanford University School of Medicine have used CRISPR in early-stage work to patch up the gene that causes sickle cell disease as they eye human trials in 2018.
Biocuba is optimistic about a future without barriers
09 November 2016
Now working without the hurdle of a trade embargo, Cuba's largest biopharma group is forging ahead with renewed optimism about the future. uring the recent BIO Latin America conference, a representative from Biocuba Farma, of Havana, said that positive outlook was built since the administration of U.S. President Barack Obama lifted a long-standing embargo against the Caribbean island.
Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development
08 November 2016
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Rick McElheny has been named Vice President, Business Development.
Attorneys counsel at-ready stance on cyber-attacks
08 November 2016
The rising tide of digital attacks touching politics, finance and retail also poses significant threats for the pharmaceutical and medical device industries. During a Thursday webinar, attorneys at King & Spalding LLP counseled that internal identification of "crown jewel" trade secrets, rigorous protection plans and an at-ready stance for incident response to thefts should form the core of corporate game plans.
Synthetic virus may drive personalized medicine into precision medicine
08 November 2016
A collaborative effort involving Auburn University, Gen9 and Autodesk has developed a synthetic viral genome for bone cancer research and one which may prove revolutionary in the battle against cancer overall.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024